QPPV.COM KNOWLEDGE ASSESSMENT

Pharmacoepidemiology in Pharmacovigilance: Professional Knowledge Assessment

Test your understanding of the concepts covered by Pharmacoepidemiology in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes why sensitivity analyses are valuable in pharmacoepidemiology?

They demonstrate that no uncertainty remains. They test whether conclusions are robust to reasonable alternative definitions, follow-up periods or analytical assumptions. They replace the need for a primary analysis and prespecified protocol. They correct all errors caused by inaccurate data capture.

Question 2 of 10 Which approach best reflects the article's recommended interpretation of an observational association?

Treat the association as causal unless a randomised trial disproves it. Treat the association as irrelevant because confounding is possible. Assess alternative explanations, temporal sequence, biological plausibility, consistency and the totality of evidence. Rely primarily on the most statistically complex model.

Question 3 of 10 A cohort analysis counts a period during which treated patients had to remain outcome-free in order to be classified as exposed. What problem could this create?

Immortal time bias, potentially exaggerating treatment benefit. Healthy adherer bias, which only affects vaccine studies. Ecological bias, because the data are individual-level. Information bias, which is eliminated by longer follow-up.

Question 4 of 10 A sponsor proposes a PASS using a database that is large but does not capture the exposure or outcome with adequate validity. What is the key regulatory concern?

The study is acceptable because database size is the primary determinant of validity. The data source may be inappropriate for the question, so its suitability and limitations require scientific justification. A PASS may use any data source if the analysis uses propensity scores. Data quality is relevant only to clinical trials.

Question 5 of 10 Which sequence most accurately represents the transformation from routine healthcare information to regulatory knowledge?

Real-World Evidence is collected first, then converted into Real-World Data by statistical analysis. Real-World Data are collected, pharmacoepidemiological methods analyse them, and Real-World Evidence is generated for decision-making. Spontaneous reports are converted directly into causal conclusions without analysis. Clinical trial data are required before any Real-World Data can be used.

Question 6 of 10 Which statement best distinguishes a prescription database from a dispensing database?

Prescription data record medicine supply, whereas dispensing data record clinical diagnoses. Prescription data record medicines ordered by prescribers, whereas dispensing data record medicines supplied to patients. Prescription data confirm consumption, whereas dispensing data confirm clinical indication. There is no conceptual distinction between the two sources.

Question 7 of 10 What is the most appropriate strategic role of pharmacoepidemiology for an experienced QPPV?

To complete standalone observational studies without linking them to pharmacovigilance decisions. To generate evidence that reduces uncertainty and informs benefit-risk assessment, risk management and regulatory action. To replace spontaneous reporting and clinical trial evidence. To prioritise the number of analyses completed over their regulatory relevance.

Question 8 of 10 Why might investigators use a case-crossover design for an acute event following a transient exposure?

It compares different time periods within the same individual, reducing confounding from fixed characteristics. It compares countries and therefore removes individual-level confounding. It is the preferred design for estimating prevalence at one point in time. It requires investigators to assign exposure randomly.

Question 9 of 10 Which statement best describes the role of propensity score methods?

They balance measured baseline characteristics between treatment groups but cannot address unmeasured variables. They provide randomisation after the study has begun and eliminate all bias. They are used only for descriptive drug utilisation studies. They prove that an observed association is biologically causal.

Question 10 of 10 A study uses a very large claims database but lacks reliable information on disease severity, an important confounder. What is the most appropriate interpretation?

The sample size makes the missing information irrelevant. The results may still be useful, but residual confounding could remain and should be acknowledged. Claims data are unsuitable for all pharmacoepidemiological research. Statistical significance would demonstrate that disease severity did not matter.

Pharmacoepidemiology in Pharmacovigilance: Professional Knowledge Assessment

Cookie Settings